Bicara Therapeutics Files Annual Proxy Statement
Ticker: BCAX · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 2023658
| Field | Detail |
|---|---|
| Company | Bicara Therapeutics Inc. (BCAX) |
| Form Type | DEF 14A |
| Filed Date | Apr 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, sec-filing
TL;DR
Bicara Therapeutics filed its annual proxy statement for the June 9 meeting. No fee required.
AI Summary
Bicara Therapeutics Inc. filed its definitive proxy statement on April 25, 2025, for its annual meeting on June 9, 2025. The company, located at 245 Main Street, Cambridge, MA, is in the pharmaceutical preparations industry. This filing is a routine annual disclosure and does not involve a fee.
Why It Matters
This filing provides shareholders with essential information regarding the company's governance and upcoming voting matters, allowing them to participate in corporate decisions.
Risk Assessment
Risk Level: low — This is a standard annual proxy filing (DEF 14A) with no immediate financial or operational news.
Key Numbers
- 20250425 — Filing Date (Date the definitive proxy statement was filed with the SEC.)
- 20250609 — Meeting Date (Date of the shareholder meeting for which the proxy statement is issued.)
Key Players & Entities
- Bicara Therapeutics Inc. (company) — Registrant
- 245 Main Street, Cambridge, MA 02142 (address) — Company Business and Mail Address
- 0002023658-25-000027 (filing_id) — Accession Number
FAQ
What is the purpose of this DEF 14A filing?
This filing is a definitive proxy statement filed by Bicara Therapeutics Inc. to provide shareholders with information for their upcoming annual meeting on June 9, 2025.
When was this proxy statement filed?
The definitive proxy statement was filed on April 25, 2025.
What is Bicara Therapeutics Inc.'s primary business?
Bicara Therapeutics Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
Is there a filing fee associated with this document?
No fee is required for this filing, as indicated by the 'No fee required' checkbox being selected.
What is the company's fiscal year end?
Bicara Therapeutics Inc.'s fiscal year ends on December 31.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 regarding Bicara Therapeutics Inc. (BCAX).